These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7927134)

  • 41. [Immunopathogenesis and clinical aspects of chronic GVHD after allogeneic bone marrow transplantation].
    Kubo K
    Nihon Rinsho; 1990 Sep; 48(9):2061-7. PubMed ID: 2232211
    [No Abstract]   [Full Text] [Related]  

  • 42. Cyclosporine administration practices on bone marrow transplant units: a national survey.
    Caudell KA; Adams J
    Oncol Nurs Forum; 1990; 17(4):563-8. PubMed ID: 2119035
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Grading acute graft-versus-host disease: time to reconsider.
    Goyal RK; Goyal M; Sankaranarayan K
    Pediatr Transplant; 2015 May; 19(3):252-4. PubMed ID: 25599820
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevention of post-transfusion graft-versus-host disease.
    Tasaki T; Ohto H; Abe R
    Fukushima J Med Sci; 1993 Dec; 39(2):109-11. PubMed ID: 7927133
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Extracorporeal photochemotherapy for treatment of drug-resistant graft-vs.-host disease.
    Smith EP; Sniecinski I; Dagis AC; Parker PM; Snyder DS; Stein AS; Nademanee A; O'Donnell MR; Molina A; Schmidt GM; Stepan DE; Kapoor N; Niland JC; Forman SJ
    Biol Blood Marrow Transplant; 1998; 4(1):27-37. PubMed ID: 9701389
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Graft-versus-host disease.
    Kodo H
    Nihon Ketsueki Gakkai Zasshi; 1987 Dec; 50(8):1621-6. PubMed ID: 2833846
    [No Abstract]   [Full Text] [Related]  

  • 47. Air-leak Syndrome by Pleuroparenchymal Fibroelastosis after Bone Marrow Transplantation.
    Ishii T; Bandoh S; Kanaji N; Tadokoro A; Watanabe N; Imataki O; Dobashi H; Kushida Y; Haba R; Yokomise H
    Intern Med; 2016; 55(2):105-11. PubMed ID: 26781007
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Blood transfusion and transplantation].
    Ishikura H; Endo J
    Rinsho Byori; 1991 Jul; Suppl 90():139-50. PubMed ID: 1920850
    [No Abstract]   [Full Text] [Related]  

  • 49. Graft versus host disease after blood transfusions in a premature infant.
    Funkhouser AW; Vogelsang G; Zehnbauer B; Tunnessen WW; Beschorner WE; Sanders M; Graeber JE
    Pediatrics; 1991 Feb; 87(2):247-50. PubMed ID: 1987538
    [No Abstract]   [Full Text] [Related]  

  • 50. [Treatment of transfusion-associated graft-versus-host disease].
    Yasukawa M
    Nihon Rinsho; 1997 Sep; 55(9):2290-5. PubMed ID: 9301292
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Successful therapy of refractory graft versus host disease with tacrolimus and Psoralen plus ultraviolet light.
    Jubran RF; Dinndorf PA
    Ther Drug Monit; 1998 Apr; 20(2):236-9. PubMed ID: 9558141
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Post-transfusion GVHD].
    Ito K
    Nihon Naika Gakkai Zasshi; 1996 Jun; 85(6):834-8. PubMed ID: 8753048
    [No Abstract]   [Full Text] [Related]  

  • 53. Paternal bone marrow infusion as salvage therapy for severe GVHD following maternal haploidentical transplantation resulting in biparental chimerism.
    Jaiswal SR; Chatterjee S; Chakrabarti S
    Int J Hematol; 2013 Oct; 98(4):504-8. PubMed ID: 24061772
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Transfusion support for leukaemia and oncology patients.
    Mayer K
    Clin Haematol; 1984 Feb; 13(1):93-8. PubMed ID: 6373084
    [No Abstract]   [Full Text] [Related]  

  • 55. [Clinical characteristics and evaluation of risk in the graft versus host reaction following transfusion].
    von Fliedner VE; Grob JP; Barrelet L
    Schweiz Med Wochenschr; 1983 Oct; 113(41):1521-3. PubMed ID: 6635642
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Response as an end point in treatment trials for acute GVHD.
    Pavletic SZ
    Bone Marrow Transplant; 2012 Feb; 47(2):161-3. PubMed ID: 22314205
    [No Abstract]   [Full Text] [Related]  

  • 57. [Graft versus host disease after transfusion of blood and its products].
    Molaro GL; De Angelis V
    Riv Emoter Immunoematol; 1984; 31(2):107-23. PubMed ID: 6399156
    [No Abstract]   [Full Text] [Related]  

  • 58. [Post-transfusion graft-vs-host disease].
    Ito K
    Nihon Naika Gakkai Zasshi; 1999 Mar; 88(3):532-6. PubMed ID: 10341636
    [No Abstract]   [Full Text] [Related]  

  • 59. OKT3 therapy for transfusion-associated graft-versus-host disease in a neonate.
    Murakami T; Seguchi M; Nakazawa M; Momma K
    Acta Paediatr Jpn; 1997 Aug; 39(4):462-5. PubMed ID: 9316293
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Post-transfusion graft versus host disease in a patient with Hodgkin's disease].
    Tomás Martínez JF; Abad Hernández MJ; Cortina de la Calle MP; Canut Blasco A; Nieto González MJ; Corral Alonso M; San Miguel Izquierdo JF; López-Borrasca A
    Med Clin (Barc); 1989 Apr; 92(13):503-6. PubMed ID: 2747313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.